Seattle Genetics begins trial of vadastuximab talirine combination therapy in MDS patients

US-based Seattle Genetics has started a Phase I/II clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza), a hypomethylating agent (HMA), in patients with previously untreated myelodysplastic syndrome (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news